Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) – Equities research analysts at Jefferies Financial Group reduced their FY2026 EPS estimates for Enanta Pharmaceuticals in a research note issued to investors on Monday, November 21st. Jefferies Financial Group analyst A. Tewari now forecasts that the biotechnology company will post earnings of $2.05 per share for the year, down from their prior estimate of $2.36. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($2.99) per share.
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last posted its quarterly earnings results on Monday, November 21st. The biotechnology company reported ($1.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.10. The firm had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative return on equity of 34.73%. Enanta Pharmaceuticals’s quarterly revenue was down 13.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.22) earnings per share.
Enanta Pharmaceuticals Price Performance
NASDAQ:ENTA opened at $45.00 on Wednesday. The firm has a market capitalization of $932.85 million, a price-to-earnings ratio of -7.61 and a beta of 0.53. The company’s 50-day moving average is $47.82 and its two-hundred day moving average is $51.17. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $92.90.
Institutional Investors Weigh In On Enanta Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its stake in Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company’s stock worth $28,000 after buying an additional 182 shares during the period. Nisa Investment Advisors LLC increased its stake in Enanta Pharmaceuticals by 164.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,207 shares of the biotechnology company’s stock worth $57,000 after buying an additional 750 shares during the period. Captrust Financial Advisors increased its stake in Enanta Pharmaceuticals by 343.8% during the 1st quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock worth $61,000 after buying an additional 660 shares during the period. Point72 Hong Kong Ltd increased its stake in Enanta Pharmaceuticals by 83.7% during the 2nd quarter. Point72 Hong Kong Ltd now owns 1,565 shares of the biotechnology company’s stock worth $74,000 after buying an additional 713 shares during the period. Finally, Quantbot Technologies LP increased its stake in Enanta Pharmaceuticals by 13,411.8% during the 2nd quarter. Quantbot Technologies LP now owns 2,297 shares of the biotechnology company’s stock worth $108,000 after buying an additional 2,280 shares during the period. 97.09% of the stock is owned by hedge funds and other institutional investors.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.